Keytruda Injection 100mg/4ml

Product Description

Product Name: Keytruda Injection 100mg/4ml

Product Form: Injection

Pack Size: 4ml

Manufactured By: MSD

Used For:

Pembrolizumab is approved for the treatment of various cancers, including:

1. Non-Small Cell Lung Cancer (NSCLC):

   • Used alone or in combination with chemotherapy in advanced or metastatic cases.

2. Melanoma:

   • For advanced or unresectable melanoma, often used when other treatments have failed.

3. Head and Neck Cancer:

   • For certain cases of recurrent or metastatic squamous cell carcinoma of the head and neck.

4. Classical Hodgkin Lymphoma:

   • Used for patients who have relapsed or refractory disease after prior treatments.

5. Urothelial Carcinoma:

   • For advanced bladder cancer or cancer of the urinary tract.

6. Other Cancers:

   • Pembrolizumab is also used to treat cancers such as cervical cancer, esophageal cancer, gastric cancer, and renal cell carcinoma, among others.

Side Effects:

1. Common Side Effects:

   • Fatigue
   • Rash
   • Diarrhea or colitis (inflammation of the colon)
   • Nausea
   • Loss of appetite
   • Cough
   • Shortness of breath

2. Serious Side Effects:

   • Immune-related side effects: Since pembrolizumab enhances immune activity, it can trigger inflammation in various organs, leading to:
     • Pneumonitis (inflammation of the lungs)
     • Colitis (inflammation of the colon)
     • Hepatitis (inflammation of the liver)
     • Nephritis (inflammation of the kidneys)
     • Endocrinopathies (disorders of hormone-producing glands, such as the thyroid or adrenal glands)
   • Severe allergic reactions (e.g., rash, itching, difficulty breathing)
   • Infusion-related reactions (e.g., fever, chills, low blood pressure)

3. Long-Term Side Effects:

   • Chronic inflammation: Persistent immune responses may lead to long-term issues with various organs.

Precautions:

1. Immune System Disorders:

   • Pembrolizumab can cause autoimmune reactions where the immune system attacks healthy tissues. Patients with autoimmune diseases or a history of organ transplant should discuss the use of pembrolizumab with their oncologist.

2. Pregnancy and Breastfeeding:

   • Pembrolizumab can harm a developing fetus, so it is contraindicated during pregnancy. Effective contraception should be used during treatment and for at least 4 months after the last dose. It is not recommended during breastfeeding.

3. Liver and Kidney Function:

   • Pembrolizumab can affect liver and kidney function, so regular monitoring of these organs is essential during treatment.

4. Infection Risk:

   • While it stimulates the immune system to fight cancer, it may also increase the risk of infections, particularly in people with weakened immune systems.